Home API Daclatasvir dihydrochloride

Daclatasvir dihydrochloride

Enquire Now

[anr_nocaptcha g-recaptcha-response]

What is Daclatasvir dihydrochloride?

Daclatasvir dihydrochloride is a powerful antiviral drug used with Sofosbuvir to treat Hepatitis C. It is sold under the brand name Daklinza and belongs to a drug class called NS5A inhibitors. The chemical composition of Daclatasvir dihydrochloride consists of two compounds, namely Daclatasvir and Hydrochloride Acid.

Product Description

Molar Mass: 811.8 g·mol−1
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C
InChIKey: FKRSSPOQAMALKA-CUPIEXAXSA-N
ALogP: 6.22
CAS Number: 1009119-65-6
Chemical Formula: C40H52Cl2N8O6
Therapeutic Category: AntiHCV
Form: Tablet
Assay: NLT 99.0%
Storage: 2-8C Fridge/Coldroom
Suitable for: Elderly, Children, Adult
IUPAC Name:
methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride

Approved Indication (1)

As per the clinical trials 1-4, the approved indication for Daclatasvir is Hepatitis C, Chronic.

Experimental Indication (22)

Daclatasvir has nearly 22 experimental indications, namely:

  • Carcinoma, Hepatocellular (Phase 3)
  • COVID-19 (Phase 4)
  • Diabetes Mellitus (Phase 1)
  • Drug Interactions (Phase 1)
  • Drug Misuse (Phase 4)
  • Fibrosis (Phase 4)
  • Healthy Volunteers (Phase 1)
  • Hepacivirus (Phase 3)
  • Hepatic Insufficiency (Phase 1)
  • Hepatitis B (Phase 3)
  • Hepatitis C (Phase 4)
  • Hepatitis C, Chronic (Phase 4)
  • Hepatitis, Chronic (Phase 2)
  • HIV (Phase 3)
  • HIV Infections (Phase 2)
  • Insulin Resistance (Phase 4)
  • Kidney Failure, Chronic (Phase 4)
  • Liver Diseases (Phase 1)
  • Liver Transplantation (Phase 4)
  • Metabolic Syndrome (Phase 2/Phase 3)
  • Renal Insufficiency (Phase 4)
  • Severe Acute Respiratory Syndrome (Phase 2)

Clinical Trials (148)

A total of 148 trials were held for this drug, and it took place in four phases. 133 companies took part in these trials.

Side Effects

Some common side effects that the patients can experience with Daclatasvir dihydrochloride tablet are:

  • Headache
  • Nausea
  • Diarrhea
  • Chest Pain

If you see any allergic infection using this tablet, like a rash, itch, or redness, connect with your doctor.

Conclusion

Daclatasvir dihydrochloride is a salt of Daclatasvir used to treat specific cases of chronic HCV. You can use this medicine to stop the replication of the NS5A virus, which is the major constituent of HCV. Daclatasvir dihydrochloride has a molecular mass of 811.8 gm, and its chemical formula can be written as C40H52Cl2N8O6. The common side effects of taking Daclatasvir dihydrochloride are headache, nausea, and diarrhea.

Enquire Now
close slider


[anr_nocaptcha g-recaptcha-response]




  • INQUIRY FORM

    INQUIRY FORM